Contineum Therapeutics, Inc.CTNM

Contineum Therapeutics, Inc. Segments Disclosure

10-KFiled Mar 5, 20262 min read
Segment Reporting
The Company operates in one reportable segment, pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need.
Our CODM is our President and Chief Executive Officer, Carmine Stengone. The CODM uses operating expenses, as reported on our statements of operations and comprehensive loss. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results of the Company as a whole using operating expenses. Net loss is also a measure that is considered in monitoring budget versus actual results. The CODM does not review assets in evaluating the results of the Company, and therefore, such information is not presented.
Significant segment expenses within net loss include research and development related to PIPE-791, PIPE-307, CTX-343, discovery programs and unallocated internal costs, general and administrative and interest income.
The following table provides the operating financial results of our single reportable segment (in thousands):
Years Ended
December 31,
20252024
Significant segment expenses
Research and development
PIPE-791$22,656 $11,257 
PIPE-3077,567 11,249 
CTX-3433,156 2,460 
Discovery programs5,339 4,789 
Unallocated internal costs (1)
12,804 8,667 
General and administrative16,537 12,472 
Total operating expenses68,059 50,894 
Loss from operations(68,059)(50,894)
Interest income8,246 8,905 
Other segment items (2)
(165)(269)
Net loss$(59,978)$(42,258)
______________________
(1)Unallocated internal research and development costs include employee-related expenses that cannot be directly attributable to a specific research project, stock-based compensation for employees engaged in research and development functions, facilities, depreciation and other related expenses.
(2)Other segment items primarily include change in fair value of warrant liability and other expense, net.
Free Sentinel

Want the next Contineum Therapeutics, Inc. segments disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment Contineum Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Mar 5, 2026Showing above
2024Mar 6, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesFair ValuePP&EDebtCommitmentsNew Standards